Maravai LifeSciences (NASDAQ:MRVI) Upgraded at UBS Group

Maravai LifeSciences (NASDAQ:MRVI) was upgraded by equities research analysts at UBS Group to a “hold” rating in a research note issued on Wednesday, Zacks reports.

MRVI has been the subject of several other reports. Wall Street Zen downgraded Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Wells Fargo & Company increased their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.83.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $6.53 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The firm has a fifty day moving average of $6.86 and a 200 day moving average of $5.05. The firm has a market cap of $1.70 billion, a PE ratio of -12.56 and a beta of 0.60. Maravai LifeSciences has a one year low of $2.55 and a one year high of $9.42.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The business had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. As a group, research analysts predict that Maravai LifeSciences will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MRVI. Wellington Management Group LLP purchased a new stake in shares of Maravai LifeSciences in the fourth quarter valued at approximately $7,670,000. General American Investors Co. Inc. grew its holdings in Maravai LifeSciences by 1,062.2% during the fourth quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock worth $5,152,000 after acquiring an additional 1,448,907 shares during the period. Millennium Management LLC raised its position in Maravai LifeSciences by 308.7% in the fourth quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock worth $5,840,000 after acquiring an additional 1,357,349 shares in the last quarter. Marshall Wace LLP raised its position in Maravai LifeSciences by 52.3% in the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after acquiring an additional 687,253 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Maravai LifeSciences by 64.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after acquiring an additional 558,050 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.